MedTrace Logo

suPAR is a Potential Biomarker of in Chronic Periodontitis Through the Impact of Post-radiotherapy on HNCs Patients

NCT06481059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-07-01

No results posted yet for this study

Summary

This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).

Conditions

Interventions

RADIATION

Head and Neck cancer post-radiotherapy

Head and Neck Cancer patients who received radiotherapy after 6 months

Sponsors & Collaborators

  • Al-Maarif University College

    lead OTHER

Principal Investigators

  • Ahmed A. Al-Kubaisi, PhD · Al-Maarif University College

  • Maysam A. Ghazi, MSc · Al-Maarif University College

  • Nisreen S. Majeed, MSc · Al-Maarif University College

  • Ekram R. Aldelaimi, BDS · Department of Periodontology, Al-Anbar Health Directorate, Ministry of Health

  • Hamid H. Enezei, PhD · Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Anbar

Eligibility

Min Age
28 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-01-09
Completion
2023-06-23

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06481059 on ClinicalTrials.gov